



- (51) **International Patent Classification:**
A61K 47/68 (2017.01) *A61P 35/00* (2006.01)
- (21) **International Application Number:**
PCT/US2023/080162
- (22) **International Filing Date:**
16 November 2023 (16.11.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/384,214 17 November 2022 (17.11.2022) US
22306780.2 02 December 2022 (02.12.2022) EP
63/596,943 07 November 2023 (07.11.2023) US
- (71) **Applicants:** **SANOFI** [FR/FR]; 46 avenue de la Grande Armée, 75017 Paris (FR). **SEAGEN INC.** [US/US]; 21823 30th Drive S.E., Bothell, Washington 98021 (US).
- (72) **Inventors:** **BAUDAT, Yves**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR). **BRUN, Marie-Priscille**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR). **DÉCARY, Stéphanie**; c/o Sanofi, Patent Department, 46 avenue de la

Grande Armée, 75017 Paris (FR). **JEFFREY, Scott**; c/o Seagen Inc., 21823 30th Drive S.E., Bothell, Washington 98021 (US). **LYSKI, Ryan**; c/o Seagen Inc., 21823 30th Drive S.E., Bothell, Washington 98021 (US). **NICOLAZZI, Céline**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR).

(74) **Agent:** **POON, Meghan** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) **Title:** CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF




FIG. 2

(57) **Abstract:** The present invention relates to antibody-drug conjugates comprising an antibody that binds to CEACAM5 conjugated to a drug, such as a Topoisomerase I inhibitor. Also provided herein are methods of treating cancer comprising administering such ADCs.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*